Sclerostin, Human, Control Peptide

The gene noggin encodes a member of one of at least four distinct gene families encoding secreted polypeptides that bind tomembers of the transforming growth factor-beta superfamily, suchas BMP, and inhibit the function of these signaling proteinsby preventing their interaction with receptors on the cell surface. Other antagonists with related functions includeChordin, Follistatin, Sclerostin and members of the DAN family. These BMP antagonists are assumed to be diffusibleand therefore potentially important in the establishment of BMPactivity gradients in vivo Although structurally distinct, members of these gene familieshave in some cases similar ligand specificity and overlappingpatterns of expression, and in the case of Chordin and Nogginthese proteins apparently are capable of at least partial compensationfor each other. In addition to these multiple secreted BMP antagonists, there are other secreted proteins whose primaryfunction is to overcome this antagonism. Thus, thereis a highly complex system to regulate the bioavailability andconsequently the activities of BMPs in the extracellularspace., BMPs are important regulators of key events in the processes of bone formation during embryogenesis, postnatal growth, remodeling and regeneration of the skeleton. The BMPs function by binding to a receptor complex that is found on all normal cells and is composed of type-I and -II receptors. The primary unit of bone formation is osteoblast, the bone forming cell. These osteoblast cells respond to physical loading by transducing signals that alter gene expression patterns. Cbfa (core binding factor), the osteoblast specific transcription factor plays an important role in osteoblast differentiation and function., Sclerostin (213aa in rat and human (chr 17q12) and 211aa in mouse) is a novel secreted osteoclast-derived BMP antagonist with unique ligand specificity, it negatively regulates the formation of bone by repressing the differentiation and/or function of osteoblasts induced by BMPs. Since sclerostin expression is confined to the bone resorbing osteoclast, it provides a mechanism whereby bone apposition is inhibited in the vicinity of resorption. Indicating the role of sclerostin in bone remodeling and links bone resorption and bone apposition. Defects in SOST are the cause of sclerosteosis, a progressive sclerosing bone dysplasia. Applications: Suitable for use in ELISA and Antibody Blocking. Other applications not tested. Recommended Dilution: ELISA: Control peptide can be used to coat ELISA plates at 1ug/ml and detected with antibodies. , Antibody Blocking: 5-10ug per 1ug S0501-05, Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. For long-term storage, store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.